Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Vor Biopharma
< Previous
1
2
Next >
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
July 21, 2025
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 18, 2025
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
July 17, 2025
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer
July 10, 2025
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2025
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Announces $175 Million Private Placement
June 25, 2025
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
June 25, 2025
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
May 08, 2025
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
March 20, 2025
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
February 03, 2025
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors
January 08, 2025
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Announces $55.6 Million Private Placement
December 27, 2024
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
December 09, 2024
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
November 12, 2024
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
November 07, 2024
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
September 30, 2024
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
September 05, 2024
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio to Participate in Upcoming Investor Conferences
August 28, 2024
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
August 08, 2024
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 09, 2024
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
May 09, 2024
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio to Participate in Upcoming Investor Conferences
May 06, 2024
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
May 02, 2024
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio to Participate in Upcoming Investor Conferences
April 01, 2024
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
March 20, 2024
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
Vor Bio to Participate in Upcoming Investor Conferences
March 04, 2024
From
Vor Biopharma
Via
GlobeNewswire
Tickers
VOR
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.